Just Sue It: Nike Takes Skechers to Court For Copying Design Patents

Just Sue It: Nike Takes Skechers to Court For Copying Design Patents

Nike, Inc. v. Skechers U.S.A., Inc., 2:19-cv-08418 (C.D. Cal.)

It is a footwear face-off! Popular sporting goods brand Nike recently filed a lawsuit against footwear rival Skechers, alleging infringement of Nike’s design patents. The 37-page complaint, filed by Nike in the U.S. District Court for the Central District of California on September 30th, claims that its competitor employs a “copying strategy” to sell “Skecherized versions” of its sneakers.

The “Just Do It” brand explains that the suit was filed to defend its design innovations and stop Skechers from ripping off the outputs of Nike’s significant investment in talent and resources.

The filings expressly point to Skechers’ Skech-Air Atlas, Skech-Air 92, Skech-Air Stratus and Skech-Air Blast, claiming the infringing designs are blatant replicas of Nike’s VaporMax and Air Max 270 shoes.

According to Nike, both sneakers feature their proprietary Air sole, which the company has used in their shoes since 1987 when it first appeared on the Air Max 1. Nike also recently filed design patents for their VapourMax and Air Max 270 in June and September 2019. And while the case only involves two athletic footwear models, Nike claims Skechers has infringed numerous design patents obtained on each shoe earlier this year.

A design patent is a “new, original and ornamental design for an article of manufacture,” as defined in 35 U.S.C. §171. To obtain protection for a product design, a company must show that it has a unique or distinctive shape or appearance. The design patents that Nike acquired for the VapourMax and Air Max 270 protect multiple elements of the shoe styles’ upper and sole.

In addition to the duped designs, the filings note two similar patent lawsuits against Skechers, filed by Nike in 2016 and their subsidiary, Converse, in 2014, that are still ongoing. In these pending cases, Nike alleges Skechers copied the iconic Chuck Taylor design from Converse and Nike’s patented Nike Free and Flyknit designs.

The suit also alleges that Skechers' CEO, Robert Greenberg, spearheaded the strategy to take inspiration from competitor products in an effort to gain market share. Nike claims that a Skechers corporate witness revealed instructions from Greenberg to knock off competitor designs during their testimony in a similar case against the rival company CEO.

Nike is not the only one to call Skechers a copycat. In September 2015, Skechers found itself at the center of a trademark infringement case filed by Adidas.

Nike is seeking compensation for their attorney fees, any profits Skechers made from selling the shoes, and a permanent injunction from the court on the infringing designs. We await to see how things run out!

Commentary

Even though Nike has an arsenal of design patents protecting the ornamental appearances of their Air sole units, they may still face challenges in their lawsuit. While cheaper and quicker to obtain design patents than utility patents, they generally provide a much narrower scope of protection as no functional features of the product are protected, only the ascetic features as filed in the designs. Furthermore, Nike will have to prove that Sketchers' designs are similar to Nike and substantially the same. This can be a tough bar to meet. That being said, should the courts find infringement, it would likely require Sketchers to pay Nike significant damages, including profits made due to the alleged infringement.

Athena Innovation & Legal

Athena Innovation & Legal is a reliable source for learning about copyright. You can access our blog posts by clicking the button below to expand your knowledge. Our posts cover a wide range of technical details related to copyrights.

**The information provided herein is a general background of contractual, technology and intellectual property law concepts. It does not constitute legal advice, and should not be relied upon as legal advice. Athena Innovation & Legal, nor the author, make no express or implied representations or warranties in respect of the information, including but not limited to the accuracy of the information.**

Previous
Previous

Patent Strategy & Potential Changes to Patented Medicine Regulations & Drug Pricing Legislation

Next
Next

Disruptions to the Healthcare Industry: 5 Takeaways From the 2019 Waterloo Innovation Summit